Shares of health insurance company Oscar Health (NYSE:OSCR) fell 5% in the afternoon session after Wells Fargo downgraded the stock and slashed its price target. The financial institution lowered its rating on the health insurer to “Underweight” from “Equal Weight” and cut its price target to $10 from $16.

This move reflects increasing concerns about the company’s ability to navigate challenging market dynamics. Wells Fargo’s analysis pointed to rising “exchange acuity,” a term that refers to a trend of less healthy individuals enrolling in plans, which could negatively impact pricing strategies for 2025. The firm believes Oscar’s current pricing model may not be adequate to cover the rising cost trends, leading to limited visibility for the company’s performance in the near future.

This downgrade follows a recent trend of cautious sentiment from Wall Street, including a new “Underweight” rating from Barclays in early July, which cited potential policy risks that could hinder growth.

The stock market overreacts to news, and big price drops can present good opportunities to buy high-quality stocks. Is now the time to buy Oscar Health? Access our full analysis report here, it’s free.

What Is The Market Telling Us

Oscar Health’s shares are extremely volatile and have had 58 moves greater than 5% over the last year. In that context, today’s move indicates the market considers this news meaningful but not something that would fundamentally change its perception of the business.

The previous big move we wrote about was 9 days ago when the stock dropped 15.1% on the news that Barclays assigned a Bearish rating and negative sentiment spread from a peer company. Barclays initiated coverage on the health insurance company with a bearish “Underweight” rating and a $17 price target, citing emerging policy risks that could jeopardize Oscar’s growth and margin targets. The firm pointed to potential headwinds from new integrity rules, issues with Cost-Sharing Reduction (CSR) funding, and the eventual expiration of enhanced subsidies for Affordable Care Act (ACA) plans, all of which could pressure Oscar’s performance. Adding to the negative pressure, fellow health insurer Centene (CNC) withdrew its 2025 guidance, sparking fears of broader challenges within the ACA marketplace. This news sent a ripple effect across the sector, pulling down shares of related companies, including Oscar Health, as investors grew more cautious about the industry’s outlook.